Abstract
Aim. To identify new markers using omics technologies for use as predictors of fetal growth and developmental abnormalities in gesta­tio­nal diabetes (GD). Material and methods . The long-term goal of this study is to create a unique biological sample collection that can be used to assess the risk of diabetic fetopathy (DF) and other adverse perinatal outcomes by identifying early preclinical markers. To achieve this goal, the following studies were planned for the first stage: the formation of a reference collection of biomaterial from women with a known perinatal outcome and its subsequent comprehensive analysis to identify key markers. Conducting complex experiments using genetic, immunological, and mass spectrometric approaches allows for a comprehensive assessment of molecular GD pathogenesis and the identification of complementary biomarkers. For this study, a collection of plasma samples from pregnant women in the first trimester, women in labor, amniotic fluid, and umbilical cord plasma was compiled. The resulting biomaterial samples were frozen and stored at a temperature not exceeding -80 оC. A sample of 100 women aged 18-45 years, at 34 weeks 1 day to 41 weeks 6 days of gestation, from both groups with and without GD, was included in the current study. Enzyme-­linked immunosorbent assay (ELISA) was performed on samples for a number of regulatory proteins and embryotropic antibodies, molecular genetic analysis of hemostasis gene polymorphisms, and mass spectrometric analysis of amino acids. Results . A comparative analysis revealed that pregnant women with GD were more likely to have the FGB 455 G/A fibrinogen gene poly­mor­phism (p=0,008), and their autoimmune antibody profile was altered, consistent with supraphysiological apoptosis and insulin resistance. In the absence of fetal macrosomia, maternal plasma levels of tissue plasminogen activator were lower (p=0,001). The main findings of mass spectrometry of amino acids in the blood of women with GD were lower concentrations of tryptophan (p=0,025) and γ-aminobutyric acid (p=0,023). In amniotic fluid and cord blood in GD, decreased concentrations of amino acids responsible for protein synthesis (lysine and methionine) and increased concentrations of amino acids associated with macrosomia were detected. Conclusion . The study results confirm metabolic, immune, and hemo­rheo­logical disturbances in maternal GD, associated with abnormal ami­no acid composition in cord blood and amniotic fluid in neonates with macrosomia. The identified differences in the metabolome can be con­si­dered potential markers for identifying the risk of unfavorable peri­natal outcomes.

This publication has 30 references indexed in Scilit: